Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$28.1 million.

  • Entrada Therapeutics' Free Cash Flow fell 1299.74% to -$28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.8 million, marking a year-over-year decrease of 64322.61%. This contributed to the annual value of -$44.7 million for FY2024, which is 13332.24% down from last year.
  • Entrada Therapeutics' Free Cash Flow amounted to -$28.1 million in Q3 2025, which was down 1299.74% from -$29.8 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Free Cash Flow ranged from a high of $201.7 million in Q1 2023 and a low of -$39.7 million during Q1 2025
  • Over the past 4 years, Entrada Therapeutics' median Free Cash Flow value was -$26.4 million (recorded in 2024), while the average stood at -$7.0 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 103458.88% in 2023, then tumbled by 54622.17% in 2024.
  • Quarter analysis of 4 years shows Entrada Therapeutics' Free Cash Flow stood at -$28.0 million in 2022, then soared by 82.19% to -$5.0 million in 2023, then tumbled by 546.22% to -$32.2 million in 2024, then grew by 12.71% to -$28.1 million in 2025.
  • Its Free Cash Flow stands at -$28.1 million for Q3 2025, versus -$29.8 million for Q2 2025 and -$39.7 million for Q1 2025.